Work

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer

Year: 2022

Type: article

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2021.12.173

Authors: Jennifer R. Bellon, Nabihah Tayob, David D. Yang, Jordan Tralins, Chau T. Dang, Steven J. Isakoff, Michelle DeMeo, Harold J. Burstein, Ann H. Partridge, Eric P. Winer, Ian E. Krop, Sara M. Tolaney

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Dana-Farber Brigham Cancer Center, Cornell University, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4205845193

FWCI: 2.3

Cites: 26

Cited by: 29

Related to: 10